Glucotrack receives USPTO approval for three CBGM patents

Glucotrack, Inc.

Three US patents issued by USPTO: US 12,453,494 (Oct 28, 2025), US 12,458,257 and US 12,458,258 (Nov 4, 2025).
Patents protect proprietary sensor chemistry, intravascular lead design, and low-power electronics for the CBGM platform.
The patents strengthen Glucotrack's competitive position and IP protection as it advances its implantable CBGM toward commercialization.
Glucotrack's CBGM is a long-term implantable device with up to 3-year sensor longevity, no wearable component, and direct blood glucose measurement.
The system measures glucose from blood, aiming to provide real-time readings with less lag than interstitial fluid sensors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.